New combo aims to shield bone marrow in Tough-to-Treat lung cancer
NCT ID NCT06992739
First seen May 05, 2026 · Last updated Jun 08, 2026 · Updated 5 times
Summary
This study tests whether giving trilaciclib before a chemotherapy drug (sacituzumab tirumotecan) can reduce serious side effects like low white blood cell counts in people with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to standard targeted therapy. About 49 adults will receive the combination and be monitored for blood cell changes and tumor response. The goal is to make treatment safer and more tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.